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Abstract
Estrogen receptor (ER) status is a critical biomarker in breast
cancer, in large part because the ER is the target of tamoxifen and
similar drugs. In the previous issue of Breast Cancer Research,
Neubauer and colleagues used a proteomic approach to identify
proteins that are differentially regulated by ER in breast tumors.
The authors showed that ER-negative tumors have elevated levels
of PGRMC1 (progesterone receptor membrane component-1), a
hormone receptor component and binding partner for P450
proteins. In contrast, PGRMC1 was phosphorylated in ER-positive
tumors. The staining patterns of ER and PGRMC1 were mutually
exclusive in breast tumor sections, and PGRMC1 staining was
sharply increased in hypoxic areas of the tumor. The results
suggest that PGRMC1 is a candidate biomarker for ER status and
hypoxia in breast cancer.
Hormones, acting through their receptors, drive the
proliferation of some tumor types, including breast, ovarian,
and prostate tumors. The estrogen receptor (ER) has a
profound effect on breast tumor growth and is the target for
the drugs tamoxifen and fulvestrant. In spite of the importance
of ER as a therapeutic target, ER-negative tumors have a
more aggressive character and a different metastatic pathway
than ER-positive tumors. Thus, the proteins that are nega-
tively regulated by ER may constitute biomarkers and thera-
peutic targets for breast cancer.
In the previous issue of Breast Cancer Research, Neubauer
and colleagues [1] found that PGRMC1 (progesterone
receptor membrane component-1) is elevated in ER-negative
tumors. In spite of its name, PGRMC1 is not a progesterone
receptor but binds to P450 proteins, an unknown steroid-
binding protein, and PAIR-BP1 (plasminogen activator
inhibitor mRNA-binding protein), and PGRMC1 is linked to
pro-survival signaling in cancer [2]. One caveat with the study
by Neubauer and colleagues [1] is that estrogen-containing
hormone treatments repress PGRMC1 transcription [3,4],
but PGRMC1 transcriptionin tumors was not tested.
Neubauer and colleagues also found that PGRMC1 is
phosphorylated in ER-positive tumors, suggesting that there
is an ER-regulated kinase that phosphorylates PGRMC1.
Identifying this kinase will be an interesting future direction of
the research. Another notable point in the tumor analysis is
the co-induction of PGRMC1, transferrin, and apolipoprotein
A-1 because PGRMC1 has been implicated in both iron
transport and cholesterol synthesis in model organisms [5-8].
In contrast, cytochrome b5 has the opposite expression
pattern from PGRMC1 in tumors, even though PGRMC1 is
related to cytochrome b5 structurally [9].
Our laboratory has previously shown that PGRMC1 is over-
expressed in breast tumors compared with corresponding
non-malignant tissue [10]. PGRMC1 is also overexpressed in
ovarian tumors in a manner that correlates with tumor stage
[11]. Neubauer and colleagues suggest that PGRMC1
correlates with ER status, but their conclusions are limited by
the small sample size, and it will be interesting to see this
correlation tested in a larger study. Both ER-negative status
and hypoxia correlate with poor outcome in breast cancer
[12,13], and it is possible that PGRMC1 levels will have a
similar predictive value. However, the results of Neubauer and
colleagues suggest that microarray correlations are not
sufficient to address this question since PGRMC1 may be
de-stabilized by phosphorylation in ER-positive tumors.
Neubauer and colleagues have shown that PGRMC1
induction is linked to hypoxia. This is consistent with the
earlier work of Dressman and colleagues [14], which inclu-
ded PGRMC1 in a signature of genes that predict hypoxia in
breast cancer. Furthermore, a yeast PGRMC1 homologue is
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transcriptionally induced by hypoxia, and induction requires
the SREBP homologue, Sre1+ [8]. Many important regulatory
pathways are conserved between yeast and humans, and it is
intriguing to speculate that an SREBP-dependent pathway
might trigger PGRMC1 induction in hypoxic human cells.
One of the compelling links between PGRMC1 and cancer is
the ability of the former to activate intracellular signaling,
including the Akt kinase [15]. Interestingly, Ser56 and
Ser180 are required to activate Akt after oxidative damage in
a PGRMC1-overexpressing cell line. There are two likely
mechanisms through which PGRMC1 activates Akt. First,
PGRMC1 could activate P450 proteins and produce a
metabolite or by-product (such as reactive oxygen species) that
triggers Akt phosphorylation. Second, PGRMC1 may bind
directly to an Akt activator [4]. If so, Ser56 and Ser180 could
potentially be docking sites for proteins that activate Akt,
such as PDK1. In such a scenario, we might envision
PGRMC1 as a type of adaptor protein that is directly involved
in cell signaling. In ER-negative tumors, increased PGRMC1-
to-Akt activation could increase survival signaling, of which
Akt is an important component, increasing anchorage-
independent growth and drug resistance. The paper by
Neubauer and colleagues represents an important step in
understanding this pathway.
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